Drugmakers Boost US Presence Amid Tariff Threats

Global drugmakers are boosting U.S. investments and stockpiling inventory to avoid 100% tariffs. Firms like Pfizer and Eli Lilly are expanding domestic plants.

Xurve View
洞察:

Global pharmaceutical manufacturers are significantly increasing their industrial footprint in the United States as the incoming Trump administration weighs a 100% tariff on imported branded and patented medicines. To avoid these penalties, major industry players are fast-tracking domestic production facilities, stockpiling inventory, and negotiating direct agreements with the federal government.

A 3D-printed miniature model depicting U.S. President Donald Trump, U.S. flag and word "Tariffs" in this illustration taken, April 17, 2025. REUTERS/Dado Ruvic/Illustration